

# Macular Degeneration

[View the current Macular Degeneration InDepth page on BioPortfolio.com](http://www.bioportfolio.com/indepth/Macular_Degeneration.html)

([http://www.bioportfolio.com/indepth/Macular\\_Degeneration.html](http://www.bioportfolio.com/indepth/Macular_Degeneration.html))



## Recent Publications on Macular Degeneration:

- [Anti-inflammatory drug use and age-related macular degeneration.](#)  
*PURPOSE: Basic research has shown that early processes in the development...*4th October, 2008  
University of Alabama at Birmingham School of Optometry, 1716 University- Optom Vis Sci. 2008 Oct;85(10):947-50. ([DOI Direct Link](#))
- [Visualizing the limits of low vision in detecting natural image features.](#)  
*PURPOSE: The purpose of our study was to develop a tool to visualize the...*4th October, 2008  
TNO Human Factors, P.O. Box 23, 3769 ZG Soesterberg, The Netherlands.- Optom Vis Sci. 2008 Oct;85(10):E951-62. ([DOI Direct Link](#))
- [NT-501: An ophthalmic implant of polymer-encapsulated ciliary neurotrophic factor-producing cells.](#)  
*Neurotech Pharmaceuticals Inc is developing NT-501, an implantable...*3rd October, 2008  
InCytu Inc, 701 George Washington Highway, Lincoln, RI 02865, USA. Email:- Curr Opin Mol Ther. 2008 Oct;10(5):506-15.
- [Remodeling retinal neovascularization by ALK1 gene transfection in vitro.](#)  
*PURPOSE: To explore a novel strategy for balancing retinal...*3rd October, 2008  
State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun- Invest Ophthalmol Vis Sci. 2008 Oct;49(10):4553-60. ([DOI Direct Link](#))
- [Uniformity of visual acuity measures in published studies.](#)  
*PURPOSE: To investigate the methods used in contemporary ophthalmic...*3rd October, 2008  
Department of Geriatric Medicine, Queen's University of Belfast, Belfast,- Invest Ophthalmol Vis Sci. 2008 Oct;49(10):4321-7. ([DOI Direct Link](#))
- [On call. Vitamin a and macular degeneration.](#)  
*PURPOSE: To investigate the methods used in contemporary ophthalmic...*3rd October, 2008  
- Harv Mens Health Watch. 2006 Apr;10(9):8.
- [By the way, doctor. My ophthalmologist says I have drusen scattered over the macula in both eyes and wants to check them every nine months. Could you say something about what drusen are and what they mean?](#)  
*Oxidative damage contributes to cone cell death in retinitis pigmentosa...*3rd October, 2008  
- Harv Womens Health Watch. 2008 Jul;15(11):8.
- [CENTRAL AND PERICENTRAL RETINAL SENSITIVITY AFTER MACULAR TRANSLOCATION SURGERY.](#)  
*PURPOSE:: To evaluate the separate contribution of the retina versus...*2nd October, 2008  
From the Departments of \*Ophthalmology; daggerBiostatistics and- Retina. 2008 Sep 26. ([DOI Direct Link](#))

- [EXPRESSION OF CYCLOOXYGENASE-2 IN CHOROIDDAL NEOVASCULAR MEMBRANES FROM AGE-RELATED MACULAR DEGENERATION PATIENTS.](#)  
*PURPOSE:: The objective of this study was to investigate the expression of...*2nd October, 2008  
From The Henry C. Witelson Ocular Pathology Laboratory and Registry,- Retina. 2008 Sep 26. ([DOI Direct Link](#))
- [PRIMARY INTRAVITREAL BEVACIZUMAB FOR SUBFOVEAL CHOROIDDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION: Results of the Pan-American Collaborative Retina Study Group at 12 Months Follow-up.](#)  
*PURPOSE:: To report the 12-month anatomic and Early Treatment Diabetic...*2nd October, 2008  
From the \*Retina and Vitreous Service, Clinica Oftalmologica Centro- Retina. 2008 Sep 26. ([DOI Direct Link](#))
- [Increased Expression of Glutathione Peroxidase 4 Strongly Protects Retina from Oxidative Damage.](#)  
*Oxidative damage contributes to cone cell death in retinitis pigmentosa...*1st October, 2008  
Johns Hopkins University School of Medicine, Ophthalmology and- Antioxid Redox Signal. 2008 Sep 29. ([DOI Direct Link](#))
- [Alterations of activity and intracellular distribution of the 20S proteasome in ageing retinal pigment epithelial cells.](#)  
*Age-related macular degeneration (AMD) remains high incidence and accounts...*27th September, 2008  
Department of Ophthalmology, Xijing Hospital, The Fourth Military Medical- Exp Gerontol. 2008 Sep 13. ([DOI Direct Link](#))
- [Photodynamic therapy and the development of metal-based photosensitisers.](#)  
*Photodynamic therapy (PDT) is a treatment modality that has been used in...*26th September, 2008  
Department of Chemistry, The University of Hull, Kingston-upon-Hull HU6- Met Based Drugs. 2008;2008:276109. ([DOI Direct Link](#))
- [The genomic response of the retinal pigment epithelium to light damage and retinal detachment.](#)  
*The retinal pigment epithelium (RPE) plays an essential role in...*26th September, 2008  
Department of Molecular Biology and Genetics, Johns Hopkins University- J Neurosci. 2008 Sep 24;28(39):9880-9. ([DOI Direct Link](#))
- [\[Lucentis versus Avastin--is there a light at the end of the tunnel for age-related macular degeneration patients?\]](#)  
*Age-related macular degeneration is the leading cause of blindness and...*26th September, 2008  
- Harefuah. 2008 Jul;147(7):605-6, 662.

## BioNews Results for Macular Degeneration

- [VEGF Trap-Eye Final Phase 2 Results in Age-related Macular Degeneration Presented at 2008 Retina Society Meeti](#)  
*PipelineReview: Oct 3 2008 5:00PM Matching: macular degeneration*
- [VEGF Trap-Eye Final Phase 2 Results in Age-related Macular Degeneration Presented at 2008 Retina Society Meeti](#)  
*Pharma Live: Oct 2 2008 2:26AM Matching: macular degeneration*
- [Toll-like Receptor 3 and Geographic Atrophy in Age-Related Macular Degeneration](#)  
*New England Journal of Medicine: Oct 1 2008 9:24PM Matching: macular degeneration*
- [VEGF Trap-Eye Final Phase 2 Results in Age-related Macular Degeneration Presented at 2008 Retina Society Meeti](#)  
*DiGiTAL50: Sep 29 2008 6:40AM Matching: macular degeneration*
- [VEGF Trap-Eye Final Phase 2 Results in Age-related Macular Degeneration Presented at 2008 Retina Society Meeti](#)

- Genetic Engineering News: Sep 28 2008 11:51PM Matching: macular degeneration*
- [Regeneron Pharmaceuticals \(REGN\) Reports Results from Phase 2 Study of VEGF Trap-Eye](#)  
*Street Insider: Sep 29 2008 1:25PM Matching: macular degeneration*
- [VEGF Trap-Eye Final Phase 2 Results in Age-related Macular Degeneration Presented at 2008 Retina Society Meeti](#)  
*Yahoo!: Sep 28 2008 8:35PM Matching: macular degeneration*
- [VEGF Trap-Eye Final Phase 2 Results in Age-related Macular Degeneration Presented at 2008 Retina Society Meeti](#)  
*Genetic Engineering News: Sep 28 2008 8:19PM Matching: macular degeneration*
- [VEGF Trap-Eye Final Phase 2 Results in Age-related Macular Degeneration Presented at 2008 Retina Society Meeti](#)  
*SmartBrief: Sep 28 2008 8:38PM Matching: macular degeneration*
- [SILENCE THERAPEUTICS PLC - Half-yearly Report](#)  
*SmartBrief: Sep 28 2008 8:58PM Matching: macular degeneration*
- [Regeneron Pharma and Bayer HealthCare say VEGF Trap-Eye achieves durable improvements in visual acuity - Quick](#)  
*RTTNews.com: Sep 28 2008 8:10PM Matching: macular degeneration*
- [Study Reveals Need for Increased Understanding of Age-Related Macular Degeneration](#)  
*Pharma Live: Sep 18 2008 10:18AM Matching: macular degeneration*
- [TOZAL\(R\) Nutritional Supplement Improves Vision in Common Form of Macular Degeneration](#)  
*KRON4: Sep 11 2008 1:57AM Matching: macular degeneration*
- [TOZAL\(R\) Nutritional Supplement Improves Vision in Common Form of Macular Degeneration](#)  
*KSLA: Sep 10 2008 1:28PM Matching: macular degeneration*
- [TOZAL\(R\) Nutritional Supplement Improves Vision in Common Form of Macular Degeneration](#)  
*TickerTech.com: Sep 10 2008 2:31PM Matching: macular degeneration*

#### Macular Degeneration Clinical Trials:



- [Pilot Study of Lucentis Combined With Proton Beam Irradiation in Treating Wet Age-Related Macular Degeneration](#)  
*Age-Related Macular Degeneration*

#### Macular Degeneration Patents:



- 7413864- [Treating cancer using a telomerase vaccine](#)
- 7417071- [Antioxidant triacylglycerols and lipid compositions](#)
- 7417121- [Human G-protein coupled receptor, HGPRBMY39](#)
- 7418169- [Apparatus for controlling at least one of at least two sections of at least one fiber](#)

- 7418374- [Treatment protocol generation for diseases related to angiogenesis](#)
- 7419663- [Treatment of complement-associated disorders](#)
- 7419666- [Treatment of ocular disorders](#)
- 7419779- [Modulators of angiogenesis](#)
- 7419825- [Isolation of neural stem cells using gangliosides and other surface markers](#)
- 7419829- [Vector system](#)
- 7419953- [Selective R-cadherin antagonist and methods](#)
- 7417042- [Compounds for enzyme inhibition](#)
- 7417033- [Antisense oligonucleotides capable of inhibiting the formation of capillary tubes by endothelial cells](#)
- 7413885- [Tryptophanyl-tRNA synthetase-derived polypeptides useful for the regulation of angiogenesis](#)
- 7413899- [Genes from the 20q13 amplicon and their uses](#)
- 7414050- [Inhibitors of c-fms kinase](#)
- 7414054- [3-\(arylamino\)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors](#)
- 7414055- [Inhibitors of Akt activity](#)
- 7414067- [Ophthalmic compositions for treating ocular hypertension](#)
- 7414076- [Methods and compositions for treating amyloid-related diseases](#)
- 7414139- [Catalytic antioxidants and methods of use](#)
- 7416885- [Proliferated cell lines and uses thereof](#)
- 7417023- [Targeted delivery of bioaffecting compounds for the treatment of cancer](#)
- 7419994- [4-\(substituted cycloalkylmethyl\) imidazole-2-thiones, 4-\(substituted cycloalkenylmethyl\) imidazole-2- thiones, 4-\(substituted cycloalkylmethyl\) imidazol-2-ones and 4-\(substituted cyloalkenylmethyl\) imidazol-2-ones and related compounds](#)
- 7420001- [Biaryl sulfonamides and methods for using same](#)
- 7420036- [Anti-angiogenic polypeptides](#)
- 7425620- [Fc.gamma.RIIB-specific antibodies and methods of use thereof](#)
- 7425637- [N3 alkylated benzimidazole derivatives as MEK inhibitors](#)
- 7427138- [Method and apparatus for improving visual perception](#)
- 7427625- [Substituted thiatriazaacenaphthylene-6-carbonitrile kinase inhibitors](#)
- 7427662- [Inhibition of angiogenesis and destruction of angiogenic vessels by apolipoprotein A-I and high density lipoprotein](#)
- 7427685- [Therapeutic substituted cyclopentanes](#)
- 7427690- [Multifunction "crown complexes" from amino acids and peptides for skin and hair restoration](#)
- 7429574- [4-heterocyclo-pyrrolo\[2,3d\] pyrimidine compositions and their use](#)
- 7429646- [Antibodies to human tumor necrosis factor receptor-like 2](#)
- 7429663- [7-\(Pyrimidin-4-yl\)-Imidazo\[1,2-a\]Pyrimidin-5\(1H\)-ones as GSK3.beta. inhibitors](#)
- 7425580- [\(Diaryl-methyl\)-malononitriles and their use as estrogen receptor ligands](#)
- 7425545- [Modulation of C-reactive protein expression](#)
- 7420055- [Aryl sulfonamides](#)
- 7422738- [Combined cancer treatment methods using antibodies to aminophospholipids](#)
- 7422744- [Methods of treating cancer with alphavbeta3-specific antibodies](#)
- 7422745- [Methods of treating cancer with .sub.v.alpha..beta..sub.3-specific antibodies](#)
- 7422862- [Methods for identifying modulators of apoptosis](#)
- 7423038- [Compounds and compositions as protein kinase inhibitors](#)
- 7423042- [Compounds](#)
- 7423059- [Pharmaceutically active compounds and methods of use](#)
- 7425328- [Tissue factor antibodies and uses thereof](#)
- 7425540- [Method for modification of NMDA receptors through inhibition of Src](#)
- 7429681- [Combretastatin analogs with tubulin binding activity](#)

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.

